ILMN Stock Recent News
ILMN LATEST HEADLINES
TruSight Oncology Comprehensive is the first US FDA-approved, distributable comprehensive genomic profiling IVD kit with pan-cancer companion diagnostic claims The 500+ gene biomarker test advances access to localized precision oncology for patients SAN DIEGO , Aug. 27, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced Food and Drug Administration (FDA) approval of its in vitro diagnostic (IVD) TruSight™ Oncology (TSO) Comprehensive test and its first two companion diagnostic (CDx) indications. This single test interrogates over 500 genes to profile a patient's solid tumor, helping to increase the likelihood of identifying an immuno-oncology biomarker or clinically actionable biomarkers that enable targeted therapy options or clinical trial enrollment.
Investors need to pay close attention to Illumina (ILMN) stock based on the movements in the options market lately.
Illumina completed the spin-off of GRAIL in June 2024, retaining a 14.5% stake. The company is refocusing on its core DNA sequencing business, targeting high single-digit revenue growth by 2027. Q2 2024 results showed a gross margin of 68% and a net loss of $1.988 billion, mainly due to impairments.
ILMN has shown bullish signs with price action improving, above 30-week EMA, and potential for trend change. Volume analysis indicates institutional buying, momentum is short-term bullish, and long-term momentum may soon turn bullish. Relative strength has improved since June, suggesting ILMN is outperforming the SP 500 index, making it a potential buy opportunity.
Illumina, Inc. (NASDAQ:ILMN ) Illumina 2024 Strategy Update Special Call August 13, 2024 11:00 AM ET Company Participants Salli Schwartz - Head of IR Jacob Thaysen - CEO Steve Barnard - CTO Ankur Dhingra - CFO Conference Call Participants Operator Salli Schwartz Thank you for joining us today. My name is Salli Schwartz and I'm Illumina's Head of Investor Relations.
Illumina said on Tuesday it has partnered with the Broad Institute to develop new kits that will allow large-scale gene sequencing using a novel method based on the Nobel Prize-winning CRISPR technology.
-- Company poised to accelerate revenue growth into high single digits over next three years, enabled by core genomics portfolio -- Innovations to enable development of transformative applications using multiomics -- Illumina to offer higher quality insights to customers, helping them improve the overall end-to-end workflow experience and lower cost -- Delivering double digit to teens non-GAAP diluted earnings per share growth 2025-2027 -- Illumina and the Broad Institute of MIT and Harvard announce new research partnership to advance single-cell sequencing SAN DIEGO , Aug. 13, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today is hosting a Strategy Update for investors to present its strategy and three-year financial outlook that features accelerating revenue growth and significant margin expansion. "Illumina built the foundation of the genomics industry, and we will continue leading innovation across total sequencing workflows to support the next phase of our customers' su
Evaluate Illumina's (ILMN) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
Illumina's (ILMN) Q2 earnings and revenues surpass estimates in a challenging global macroeconomic environment.
Illumina, Inc. (NASDAQ:ILMN ) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Salli Schwartz - Vice President of Investor Relations Jacob Thaysen - Chief Executive Officer Ankur Dhingra - Chief Financial Officer Conference Call Participants Vijay Kumar - Evercore ISI Conor McNamara - RBC Capital Markets Patrick Donnelly - Citi Doug Schenkel - Wolfe Research Dan Arias - Stifel Tycho Peterson - Jefferies Subha Nambi - Guggenheim Securities Puneet Souda - Leerink Partners Sung Ji Nam - Scotiabank Eve Burstein - Bernstein Research David Westenberg - Piper Sandler Dan Brennan - TD Cowen Operator Good day ladies and gentlemen and welcome to the Second Quarter 2024 Illumina Earnings Conference Call. At this time, all participants are in a listen-only mode.